Federal Register Notice
Horseracing Integrity and Safety Authority Anti-Doping and Medication Control Rule Modification
Date
Displaying 1 - 20 of 29
FTC Sues to Block Biopharmaceutical Giant Amgen from Acquisition That Would Entrench Monopoly Drugs Used to Treat Two Serious Illnesses
Date
The Federal Trade Commission is seeking to block biopharmaceutical giant Amgen Inc. from acquiring Horizon Therapeutics plc, saying the deal would allow Amgen to leverage its portfolio of blockbuster...
FTC Approves Modifications to Bristol Meyers Squibb Divestiture Agreement
Date
The Federal Trade Commission has approved certain modifications to Bristol Meyers Squibb’s, or BMS’s, Divestiture Agreements that the FTC approved and incorporated into its order as part of a consent...
FTC Approves Final Order Settling Charges that Danaher Corporation’s Acquisition of GE Biopharma Was Anticompetitive
Date
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Danaher Corporation’s acquisition of GE Biopharma would likely reduce competition in...
FTC Imposes Conditions on Danaher Corporation’s Acquisition of GE Biopharma
Date
Danaher Corporation has agreed to divest assets to settle Federal Trade Commission charges that its proposed $21.4 billion acquisition of General Electric’s biopharmaceutical business, GE Biopharma...
Mar09
FDA / FTC Workshop on a Competitive Marketplace for Biosimilars
-
The Federal Trade Commission in collaboration with the Food and Drug Administration held a public workshop, "FDA/FTC Workshop on a Competitive Marketplace for Biosimilars." The purpose of the public...
FTC, FDA to Hold Workshop on Promoting Competition in Markets for Biologics
Date
On March 9, 2020, the Federal Trade Commission and the Food and Drug Administration will co-sponsor a public workshop on promoting competition in biologics markets. The workshop will be held at the...
FTC, FDA Sign Joint Statement Promoting Competition in Markets for Biologics
Date
Federal Trade Commission Chairman Joseph J. Simons today joined Food and Drug Administration Commissioner Stephen Hahn in signing a joint statement promoting competition in biologics markets....
Joint FDA-FTC Statement Regarding Collaboration to Advance Competition in the Biologic Marketplace
Date
Matter Number
V190003
FTC Approves Final Order Requiring Bristol-Myers Squibb Company and Celgene Corporation to Divest Psoriasis Drug Otezla as a Condition of Acquisition
Date
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Bristol-Myers Squibb Company’s proposed $74 billion acquisition of Celgene Corporation...
FTC Requires Bristol-Myers Squibb Company and Celgene Corporation to Divest Psoriasis Drug Otezla as a Condition of Acquisition
Date
Pharmaceutical and biologic manufacturers Bristol-Myers Squibb Company, or BMS, and Celgene Corporation have agreed to divest Celgene’s Otezla, the most popular oral treatment in the United States for...
FTC to Hold Workshop on Examining Competition Issues Related to Prescription Drug Markets
Date
WHAT: The Federal Trade Commission will host a workshop, “Understanding Competition in Prescription Drug Markets: Entry and Supply Chain Dynamics”. Acting FTC Chairman Maureen K. Ohlhausen and U.S...
FTC Staff Issues FY 2015 Report on Branded Drug Firms’ Patent Settlements with Generic Competitors
Date
The number of reverse-payment patent settlements entered into by pharmaceutical companies in fiscal year 2015 declined from fiscal year 2014, marking a second annual decrease in such settlements...
FTC Announces Agenda for November 8 Workshop on Examining Competition Issues Related to Prescription Drug Markets
Date
The Federal Trade Commission has announced an agenda for its upcoming workshop on competition issues related to prescription drug markets. The workshop, titled “Understanding Competition in...
FTC to Conduct Workshop on November 8, Examining Competition Issues Related to Prescription Drug Markets
Date
The Federal Trade Commission will hold a workshop on November 8, 2017 entitled, “Understanding Competition in Prescription Drug Markets: Entry and Supply Chain Dynamics.” Acting FTC Chairman Maureen K...
Feb04
Follow-On Biologics Workshop: Impact of Recent Legislative and Regulatory Naming Proposals on Competition
-
The Federal Trade Commission held a workshop to explore competition issues involving biologic medicines and follow-on biologics. As described in the Federal Register Notice, the workshop focused on a...
How to Submit Your Questions Online During FTC’s Biosimilars Workshop
Date
The Federal Trade Commission is hosting a workshop on competition issues surrounding biologics and follow-on biologic medicines on Feb. 4, 2014, in Washington, DC, and invites live webcast viewers to...
Displaying 1 - 20 of 29